<DOC>
	<DOCNO>NCT02062684</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety subcutaneous blisibimod administration addition standard therapy patient biopsy proven IgA Nephropathy persistent proteinuria 1-6 g/day .</brief_summary>
	<brief_title>BRIGHT-SC : Blisibimod Response IgA Nephropathy Following At-Home Treatment Subcutaneous Administration</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>18 65 year age , inclusive Biopsyproven IgA nephropathy Receiving stable , clinicallyoptimized ACEI and/or ARB Proteinuria ≥ 1g/24hr ≤ 6g/24hr 2 consecutive time point Clinical histologic evidence nonIgArelated glomerulonephritis IgA nephropathy great 50 % glomerulosclerosis cortical scar Meets eGFR criterion History treatment oral parenteral corticosteroid within 3 month immunosuppressant within 6 month Malignancy within past 5 year Known positive HIV and/or positive screen visit hepatitis B , hepatitis C Liver disease Neutropenia Active infection require hospitalization treatment parenteral antibiotic within past 60 day history repeat herpetic viral infection History active tuberculosis history tuberculosis infection Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>IgAN</keyword>
	<keyword>IgA Nephropathy</keyword>
	<keyword>A-623</keyword>
	<keyword>Blisibimod</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Persistent proteinuria</keyword>
</DOC>